Antihyperlipidemic action of a Traditional Chinese Medicine (kampo medicine), Ogi-Keishi-Gomotsu-To-Ka-Kojin.
The antihyperlipidemic action of Ogi-Keishi-Gomotsu-To-Ka-Kojin (OKGK) was examined in rats with experimentally-induced hyperlipidemia. Oral administration of OKGK at 0.69 or 1.38 g/kg/day significantly reduced the increase of serum triglycerides (TG) and phospholipids (PL). OKGK given as a nutritional supplement (1.25%) in the diet significantly suppressed the increase of serum TG and PL in rats with hypercholesterolemia induced by a cholesterol and fat-enriched diet. These results suggest the effectiveness of OKGK in the treatment of hypertriglyceridemia induced by both endogenous and exogenous TG. The mechanism by which OKGK shows antihy-pertriglyceridemic action was investigated in detail. OKGK decreased [(14)C] acetic acid incorporation into TG and PL but not fatty acids in primary cultured rat hepatocytes from rats treated with oral OKGK for 1 week. OKGK also reduced [(3)H] oleic acid into TG and PL, suggesting OKGK suppresses TG and PL syntheses in the liver. Furthermore, OKGK enhanced the activities of lipoprotein lipase (LPL) and hepatic TG lipase (HTGL) in postheparin plasma. These results suggest OKGK inhibits triglyceride synthesis in the liver and stimulates the hydrolysis of TG in lipoprotein.